These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 3119655

  • 1. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A, Fulghesu AM, Spina MA, Apa R, Menini E, Caruso A, Mancuso S.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
    [Abstract] [Full Text] [Related]

  • 2. GnRH agonist administration in polycystic ovary syndrome.
    Buckler HM, Phillips SE, Kovacs GT, Burger HG, Healy DL.
    Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
    [Abstract] [Full Text] [Related]

  • 3. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
    Fulghesu AM, Lanzone A, Guida C, Nicoletti MC, Rossi P, Le Donne M, Caruso A, Mancuso S.
    J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles.
    Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, Caruso A, Mancuso S.
    Fertil Steril; 1994 Jul; 62(1):35-41. PubMed ID: 8005301
    [Abstract] [Full Text] [Related]

  • 8. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J, Rabinovici J, Goldenberg M, Shaley J, Mehta A, Serr DM, Mashiach S.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [Abstract] [Full Text] [Related]

  • 9. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 10. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome.
    Noci I, Maggi M, Fuzzi B, Biagiotti R, Ricci F, Marchionni M.
    Gynecol Endocrinol; 2000 Oct; 14(5):321-6. PubMed ID: 11109971
    [Abstract] [Full Text] [Related]

  • 11. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M, Flamigni C, Campaniello E, Valdiserri A, Ferrari P, Meriggiola MC, Michelacci L, Pareschi A.
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Induction of ovulation by intermittent intravenous purified follicle-stimulating hormone in polycystic ovarian disease.
    Lanzone A, Fulghesu AM, Conte M, Apa R, Caruso A, Mancuso S.
    Fertil Steril; 1987 Dec; 48(6):1058-61. PubMed ID: 3119371
    [Abstract] [Full Text] [Related]

  • 14. Importance of echographic and endocrine monitoring for the assessment of ovulation by follicle stimulating hormone in polycystic ovarian disease.
    Caruso A, Lanzone A, Fulghesu AM, Apa R, Guida C, Mancuso S.
    Int J Gynaecol Obstet; 1989 Feb; 28(2):163-9. PubMed ID: 2563704
    [Abstract] [Full Text] [Related]

  • 15. [Ovulation induction with pulsatile gonadotropin-releasing hormone and continuous human menopausal gonadotropin in polycystic ovarian disease].
    Kuroda G.
    Nihon Naibunpi Gakkai Zasshi; 1987 Mar 20; 63(3):247-59. PubMed ID: 3111899
    [Abstract] [Full Text] [Related]

  • 16. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.
    Bregieiro LO, de Moura MD, Ferriani RA, Bailão LA, de Sá MF.
    Int J Fertil Menopausal Stud; 1993 Mar 20; 38(3):152-9. PubMed ID: 8348163
    [Abstract] [Full Text] [Related]

  • 17. Acute ovarian responses to a long-acting agonist of gonadotropin-releasing hormone in ovulatory women and women with polycystic ovarian disease.
    DeFazio J, Meldrum DR, Lu JK, Vale WW, Rivier JE, Judd HL, Chang RJ.
    Fertil Steril; 1985 Oct 20; 44(4):453-9. PubMed ID: 3932097
    [Abstract] [Full Text] [Related]

  • 18. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY.
    Hum Reprod; 2005 May 20; 20(5):1213-20. PubMed ID: 15760966
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The relationship between follicle-stimulating hormone dose and level and its relevance for ovulation induction with adjuvant gonadotropin-releasing hormone-agonist treatment.
    Scheele F, Hompes PG, van der Meer M, Schoute E, Schoemaker J.
    Fertil Steril; 1993 Oct 20; 60(4):620-5. PubMed ID: 8405514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.